This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kennedy, R. D. Articles by Harkin, D. P. Search for Related Content PubMed PubMed Citation Articles by Kennedy, R. D. Articles by Harkin, D. P.

BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible Gene

¹ Cancer Research Centre, Queen's University Belfast; Departments of ² Pathology and ³ Medical Genetics, Belfast City Hospital, Belfast, United Kingdom; ⁴ Department of Pathology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; ⁵ Arradx Ltd., Craigavon, United Kingdom; and ⁶ European Molecular Biology Laboratory, Heidelberg, Germany

Requests for reprints: D. Paul Harkin, Cancer Research Centre, Queen's University Belfast, University Floor, Belfast City Hospital, Belfast BT9 7AB, United Kingdom. Phone: 44-2890329241; Fax: 44-2890263744; E-mail: d.harkin{at}qub.ac.uk.

Evidence is accumulating to suggest that some of the diverse functions associated with BRCA1 may relate to its ability to transcriptionally regulate key downstream target genes. Here, we identify S100A7 (psoriasin), S100A8, and S100A9, members of the S100A family of calcium-binding proteins, as novel BRCA1-repressed targets. We show that functional BRCA1 is required for repression of these family members and that a BRCA1 disease–associated mutation abrogates BRCA1-mediated repression of psoriasin. Furthermore, we show that BRCA1 and c-Myc form a complex on the psoriasin promoter and that BRCA1-mediated repression of psoriasin is dependent on functional c-Myc. Finally, we show that psoriasin expression is induced by the topoisomerase II poison, etoposide, in the absence of functional BRCA1 and increased psoriasin expression enhances cellular sensitivity to this chemotherapeutic agent. Therefore, we identified a novel transcriptional mechanism that is likely to contribute to BRCA1-mediated resistance to etoposide.

This article has been cited by other articles:

				R. Ralhan, L. V. DeSouza, A. Matta, S. Chandra Tripathi, S. Ghanny, S. Datta Gupta, S. Bahadur, and K. W. M. Siu Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2008; 7(6): 1162 - 1173. [Abstract] [Full Text] [PDF]

				A. M. Hosey, J. J. Gorski, M. M. Murray, J. E. Quinn, W. Y. Chung, G. E. Stewart, C. R. James, S. M. Farragher, J. M. Mulligan, A. N. Scott, et al. Molecular Basis for Estrogen Receptor {alpha} Deficiency in BRCA1-Linked Breast Cancer J Natl Cancer Inst, November 21, 2007; 99(22): 1683 - 1694. [Abstract] [Full Text] [PDF]

				A. A. Horwitz, E. B. Affar, G. F. Heine, Y. Shi, and J. D. Parvin A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase PNAS, April 17, 2007; 104(16): 6614 - 6619. [Abstract] [Full Text] [PDF]

				N. E. Buckley, A. M. Hosey, J. J. Gorski, J. W. Purcell, J. M. Mulligan, D. P. Harkin, and P. B. Mullan BRCA1 Regulates IFN-{gamma} Signaling through a Mechanism Involving the Type I IFNs Mol. Cancer Res., March 1, 2007; 5(3): 261 - 270. [Abstract] [Full Text] [PDF]